CL2024004060A1 - Compuestos heterocíclicos inhibidores de axl; composición farmacéutica; uso para tratar cáncer. - Google Patents
Compuestos heterocíclicos inhibidores de axl; composición farmacéutica; uso para tratar cáncer.Info
- Publication number
- CL2024004060A1 CL2024004060A1 CL2024004060A CL2024004060A CL2024004060A1 CL 2024004060 A1 CL2024004060 A1 CL 2024004060A1 CL 2024004060 A CL2024004060 A CL 2024004060A CL 2024004060 A CL2024004060 A CL 2024004060A CL 2024004060 A1 CL2024004060 A1 CL 2024004060A1
- Authority
- CL
- Chile
- Prior art keywords
- heterocyclic
- pharmaceutical composition
- treating cancer
- axl inhibitors
- axl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263356421P | 2022-06-28 | 2022-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024004060A1 true CL2024004060A1 (es) | 2025-05-16 |
Family
ID=89324379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024004060A CL2024004060A1 (es) | 2022-06-28 | 2024-12-27 | Compuestos heterocíclicos inhibidores de axl; composición farmacéutica; uso para tratar cáncer. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20230416277A1 (https=) |
| EP (1) | EP4547246A2 (https=) |
| JP (2) | JP7785209B2 (https=) |
| KR (1) | KR20250027650A (https=) |
| CN (1) | CN119365453A (https=) |
| AR (1) | AR129722A1 (https=) |
| AU (1) | AU2023298047A1 (https=) |
| CA (1) | CA3260468A1 (https=) |
| CL (1) | CL2024004060A1 (https=) |
| IL (1) | IL317736A (https=) |
| MX (1) | MX2024015648A (https=) |
| TW (1) | TW202400603A (https=) |
| WO (1) | WO2024006726A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR129722A1 (es) | 2022-06-28 | 2024-09-18 | Arcus Biosciences Inc | Compuestos inhibidores de axl |
| WO2024233360A1 (en) | 2023-05-05 | 2024-11-14 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4720055A1 (en) | 2023-05-25 | 2026-04-08 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US20260116868A1 (en) | 2023-10-06 | 2026-04-30 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202523302A (zh) | 2023-11-02 | 2025-06-16 | 美商阿克思生物科學有限公司 | 噻唑化合物及其使用方法 |
| WO2025137370A1 (en) * | 2023-12-20 | 2025-06-26 | Arcus Biosciences, Inc. | Salt forms of an axl inhibitor |
| WO2025250276A1 (en) * | 2024-05-28 | 2025-12-04 | Taiho Pharmaceutical Co., Ltd. | Methods for treatment of non-small cell lung cancers |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| EP1828180A4 (en) * | 2004-12-08 | 2010-09-15 | Glaxosmithkline Llc | 1H-pyrrolo [2,3-BETA] PYRIDINE |
| PT1906965E (pt) * | 2005-06-22 | 2015-09-03 | Chemocentryx Inc | Compostos de azaindazol e métodos de utilização |
| CA2710046C (en) | 2006-12-29 | 2016-02-09 | Rigel Pharmaceuticals, Inc. | N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors |
| EP2078010B1 (en) | 2006-12-29 | 2014-01-29 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| JP2010514810A (ja) | 2006-12-29 | 2010-05-06 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｘｌインヒビターとして有用な置換トリアゾール |
| ES2537480T3 (es) | 2008-07-09 | 2015-06-08 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con heteroarilo policíclicos útiles como inhibidores de Axl |
| PL2387395T3 (pl) | 2009-01-16 | 2015-03-31 | Rigel Pharmaceuticals Inc | Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym |
| EP3444251B1 (en) * | 2013-12-11 | 2023-06-07 | Biogen MA Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| CN112243439A (zh) * | 2018-06-13 | 2021-01-19 | 百济神州有限公司 | 作为hpk1抑制剂的吡咯并[2,3-b]吡啶或吡咯并[2,3-b]吡嗪及其用途 |
| CA3108732A1 (en) * | 2018-08-28 | 2020-03-05 | Merck Patent Gmbh | Fused imidazopyridines as reversible inhibitors of bruton's tyrosine kinase (btk) |
| WO2020103896A1 (en) * | 2018-11-22 | 2020-05-28 | Beigene, Ltd. | Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof |
| TWI848141B (zh) | 2019-07-04 | 2024-07-11 | 英屬開曼群島商百濟神州有限公司 | 及其用途 |
| US12459958B2 (en) * | 2019-07-17 | 2025-11-04 | Beone Medicines I Gmbh | Tricyclic compounds as HPK1 inhibitor and the use thereof |
| ES3060629T3 (en) * | 2019-10-30 | 2026-03-27 | Biogen Ma Inc | Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase |
| WO2021239133A1 (zh) | 2020-05-29 | 2021-12-02 | 南京正大天晴制药有限公司 | 作为axl抑制剂的嘧啶类化合物 |
| WO2022184152A1 (zh) | 2021-03-03 | 2022-09-09 | 劲方医药科技(上海)有限公司 | 稠环取代的六元杂环化合物及其制法和用途 |
| EP4341261A1 (en) * | 2021-05-21 | 2024-03-27 | Arcus Biosciences, Inc. | Axl compounds |
| WO2022246179A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
| CN115504967A (zh) | 2021-06-23 | 2022-12-23 | 南京正大天晴制药有限公司 | 作为axl抑制剂的1,2,4-三唑化合物 |
| AR129722A1 (es) | 2022-06-28 | 2024-09-18 | Arcus Biosciences Inc | Compuestos inhibidores de axl |
-
2023
- 2023-06-26 AR ARP230101639A patent/AR129722A1/es unknown
- 2023-06-27 US US18/341,844 patent/US20230416277A1/en active Pending
- 2023-06-27 AU AU2023298047A patent/AU2023298047A1/en active Pending
- 2023-06-27 CN CN202380047386.9A patent/CN119365453A/zh active Pending
- 2023-06-27 CA CA3260468A patent/CA3260468A1/en active Pending
- 2023-06-27 WO PCT/US2023/069124 patent/WO2024006726A2/en not_active Ceased
- 2023-06-27 JP JP2024574683A patent/JP7785209B2/ja active Active
- 2023-06-27 EP EP23832486.7A patent/EP4547246A2/en active Pending
- 2023-06-27 TW TW112123754A patent/TW202400603A/zh unknown
- 2023-06-27 KR KR1020247041573A patent/KR20250027650A/ko active Pending
- 2023-06-27 IL IL317736A patent/IL317736A/en unknown
-
2024
- 2024-08-14 US US18/805,490 patent/US12195482B1/en active Active
- 2024-12-16 MX MX2024015648A patent/MX2024015648A/es unknown
- 2024-12-27 CL CL2024004060A patent/CL2024004060A1/es unknown
-
2025
- 2025-12-02 JP JP2025216661A patent/JP2026041858A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230416277A1 (en) | 2023-12-28 |
| WO2024006726A3 (en) | 2024-04-25 |
| AR129722A1 (es) | 2024-09-18 |
| KR20250027650A (ko) | 2025-02-27 |
| WO2024006726A2 (en) | 2024-01-04 |
| JP2026041858A (ja) | 2026-03-10 |
| US12195482B1 (en) | 2025-01-14 |
| TW202400603A (zh) | 2024-01-01 |
| CA3260468A1 (en) | 2024-01-04 |
| MX2024015648A (es) | 2025-02-10 |
| EP4547246A2 (en) | 2025-05-07 |
| AU2023298047A1 (en) | 2025-01-09 |
| JP7785209B2 (ja) | 2025-12-12 |
| JP2025525364A (ja) | 2025-08-05 |
| IL317736A (en) | 2025-02-01 |
| US20240425526A1 (en) | 2024-12-26 |
| CN119365453A (zh) | 2025-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024004060A1 (es) | Compuestos heterocíclicos inhibidores de axl; composición farmacéutica; uso para tratar cáncer. | |
| CR20250500A (es) | Inhibidores de kras de 2-azabiciclo [2.2.1] heptano | |
| CO2022013274A2 (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa | |
| MX2024001894A (es) | Compuestos heterociclicos y metodos de uso. | |
| BR112022012641A2 (pt) | Compostos tricíclicos substituídos | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| BR112022010383A2 (pt) | Compostos tricíclicos substituídos | |
| AR126251A1 (es) | Inhibidores de cdk2 | |
| MX2024009062A (es) | Derivados espirociclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos. | |
| ECSP066653A (es) | Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad | |
| AR058338A1 (es) | Derivados de pirrol fusionado, composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la quinasa. | |
| MX2025002817A (es) | Compuestos para el tratamiento del cancer | |
| MX2024011755A (es) | Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2) | |
| BR112023015425A2 (pt) | Derivados de uracila como inibidores de trpa1 | |
| MX2023003731A (es) | Compuestos de 3-[(1h-pirazol-4-il)oxi]pirazin-2-amina como inhibidores de hpk1, y uso de los mismos. | |
| AR133953A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| MX2023004009A (es) | Derivados de tetrazol como inhibidores de trpa1. | |
| CO2025016647A2 (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| SA522441973B1 (ar) | Trpa1 مشتقات تترازول كمثبطات لـ | |
| CL2025002792A1 (es) | Compuesto y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores | |
| WO2023150291A3 (en) | Heterocyclic compounds and methods of use | |
| MX2023015490A (es) | Inhibidores de las transglutaminasas. | |
| MX2023014784A (es) | Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos. | |
| CR20220667A (es) | Derivados de tetrazol como inhibidores de trpa1 | |
| AR128426A1 (es) | Compuestos heterocíclicos y métodos de uso |